Trial Profile
External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone in Leber's Hereditary Optic Neuropathy (LHON)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Idebenone (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Therapeutic Use
- Acronyms LEROS
- Sponsors Santhera Pharmaceuticals
- 08 Mar 2024 This trial has been completed in Italy according to European Clinical Trials Database record.
- 28 Jun 2022 Results reporting long-term clinical treatment benefit presented at the 8th Congress of the European Academy of Neurology
- 10 Jun 2022 According to Santhera Pharmaceuticals media release, reimbursement discussions are ongoing for Raxone and these are expected to be supported by the recently successfully completed Phase 4 trials LEROS and PAROS with Raxone in the rare ophthalmic indication Lebers hereditary optic neuropathy (LHON).